Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA-PRIT 2.0 in Metastatic Colorectal Cancer
NCT07416552Phase 1Recruiting
- Sponsor
- Roche
- Start
- Oct 2026
- Primary completion
- Feb 2034
- Modality
- Bispecific Antibodies, Alpha Emitters
- Countries
- 1
01
Overview
Phase 1, open-label trial of 212Pb-CEA PRIT in colorectal cancer (CRC) (3 arms), sponsored by Roche. Primary endpoints: Serum Concentration of SPLIT Abs at 48 weeks, Time Course of Blood, Plasma, and Urine Radioactivity for 203Pb-DOTAM at 48 weeks and 2 more. Started Oct 2026; status: recruiting.
02
Drugs
212Pb-CEA PRIT
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07416552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416552.